Victor Cruz Urrutia, MD

Photos

601 N Caroline St Fl 5
Baltimore, MD 21287
Dr. Victor Urrutia serves as the medical director of the stroke service at The Johns Hopkins Hospital and director of the Sheikh Khalifa Stroke Institute. He focuses on the clinical aspects of cerebrovascular disease (stroke), specifically acute stroke therapy and prevention.Dr. Urrutia currently sees patients at the Stroke Prevention Clinic, located in the Johns Hopkins Outpatient Center in Baltimore on Wednesdays, and cares for patients in The Johns Hopkins Hospital's Brain Rescue Unit.Dr. Victor Urrutia received his medical degree from the University of Panama School of Medicine. He completed his neurology training at MCP Hahnemann University in Philadelphia, now Drexel University College of Medicine. After his residency training, he completed fellowship training in neurocritical care and acute stroke at Drexel University College of Medicine and became a faculty member in the neurocritical care and acute stroke division. He then returned to Panama for two years where he was the first to treat patients with IV thrombolytic therapy for acute stroke.
Owner verified
See a problem?

You might also like

Gloria Hong, MD
Internal medicine practitioners, Testing laboratories

Gloria Hong, MD

Dr. Kelvin K. Hong is an Associate Professor and Executive Vice Chair of Radiology within the Johns Hopkins Department of Radiology.A specialist in interventional and vascular radiology, Dr. Hong serves as the Medical Director of the Johns Hopkins Interventional Radiology Center.Dr. Hong earned his medical degree from South Africa’s University Of Witwatersrand Medical School in Parktown. He completed a radiology residency at Parktown West’s College of Medicine/Radiology, as well as a cardiovascular/interventional radiology fellowship and diagnostic radiology residency at The Johns Hopkins Hospital.His areas of clinical expertise include bone, liver and soft-tissue tumors; chronic total occlusions; claudication; deep venous thrombosis; lung, esophageal and kidney cancer; peripheral arterial/vascular disease; renal artery/vascular disease; uterine fibroid tumors; varicocele; and vascular malformations and venous thromboembolism.Dr. Hong performs procedures that include radiofrequency ablation for lung, liver, kidney and bone lesions; transcatheter arterial chemoembolization for liver cancer; lower-extremity angioplasty and stenting; visceral angioplasty and stenting; embolization of uterine fibroid tumors; cryoablation for pain control; and percutaneous laser ablation of varicose veins.Dr. Hong served as editor for the book Percutaneous Tumor Ablation and contributed to Interventional Oncology: Principles and Practice.
Max Kates, MD

Max Kates, MD

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009.
United StatesMarylandBaltimoreVictor Cruz Urrutia, MD

Yext